Claims

1. Use of dopamine partial agonists and their physiologically compatible salts for producing a pharmaceutical agent for oral administration for treatment of the restless leg syndrome.

2. Use according to claim 1, characterized in that the dopamine partial agonists are selected from the following group:

terguride (trans-dihydrolisuride),

cis-dihydrolisuride,

dihydrolisuride (racemate),

2-chloro-terguride,

2-chloro-lisuride,

SDZ 208-912,

preclamol ((-)-3-PPP,

N1-allyl-terguride.

3. Use according to claim 2, wherein the terguride is administered in a dosage of 0.5 - 50 mg /day.

4. Use according to claim 3, wherein the terguride is administered in a dosage of 0.5 - 2.5 mg /day.

5. Use according to one of claims 1 to 4, wherein the dopamine partial agonist is used in combination with other pharmaceutical substances.

6. Pharmaceutical preparation for treatment of the restless leg syndrome, which contains

at least one dopamine partial agonist or its physiologically compatible salts and which is formulated for oral administration.

7. Pharmaceutical preparation according to claim 6, wherein the dopamine partial agonists are selected from the following group:

terguride (trans-dihydrolisuride),

cis-dihydrolisuride,

dihydrolisuride (racemate),

2-chloro-terguride,

2-chloro-lisuride,

SDZ 208-912,

preclamol ((-)-3-PPP),

N1-allyl-terguride.

8. Pharmaceutical preparation according to claim 7, wherein the pharmaceutical preparation terguride contains a dosage of 0.5 - 50 mg/day.

9. Pharmaceutical preparation according to claim 8, wherein the terguride is administered in a dosage of 0.5 - 2.5 mg /day.

10. Pharmaceutical preparation according to one of claims 6 to 9, wherein the dopamine partial agonist is contained in combination with other pharmaceutical substances.

11. Pharmaceutical preparation according to one of claims 6 to 10, wherein the terguride is contained alone or in combination with galenical adjuvants.